Skip to Main Content
Contribute Try STAT+ Today

Eli Lilly’s experimental Alzheimer’s medicine donanemab showed some of the best early results seen by pharmaceutical researchers in the field. What divides many researchers is whether that is a reason for excitement or not.

The results, released Saturday at the International Conference on Alzheimer’s & Parkinson Diseases  and published in the New England Journal of Medicine, are from a Phase 2 study, usually used by pharmaceutical companies to test whether a drug merits testing in a larger Phase 3 study that could result in approval. While top-line results were previously outlined in a Lilly press release, they represent a high watermark for studies in Alzheimer’s. This is the first time a Phase 2 study of a drug that attempts to slow Alzheimer’s, not just allay patients’ symptoms, has had a positive outcome.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Encouraging news from Lilly suggests provides more evidence that medicines targeted to amyloid can alter the course of AD, and that investigators are learning how to use this strategy effectively. This is part of the normative experience that a mature body of basic research is requisite for successful drug development.

Comments are closed.